Login to Your Account

Savior or Scavenger?

Otsuka Emerges as Highest Bidder; Snags Astex for $886M in Cash

By Marie Powers
Staff Writer

Friday, September 6, 2013
The lawyers began circling within hours of the official disclosure of the bid by Japan’s Otsuka Pharmaceutical Co. Ltd. for Astex Pharmaceuticals Inc. Days earlier, the Dublin, Calif.-based oncology drug developer reported positive top-line results from the Phase II trial of cancer candidate SGI-110 in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription